PepGen Inc. (PEPG)
NASDAQ$1.095
Market Cap
$35.8M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
748 of 896
Rank in Industry
422 of 514
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
PEPG Insider Trading Activity
PEPG Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $1,044,766 | 15 | 100 |
Related Transactions
| DeLena Mary Beth | General Counsel | 0 | $0 | 1 | $2,406 | $-2,406 |
| Donnelly Noel | Chief Financial Officer | 0 | $0 | 1 | $2,565 | $-2,565 |
| Svenstrup Niels | SVP, Chem. Mfg & Controls | 0 | $0 | 1 | $134,100 | $-134,100 |
| Mellion Michelle L | SVP, Clinical Development | 0 | $0 | 12 | $905,695 | $-905,695 |
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the …
Insider Activity of PepGen Inc.
Over the last 12 months, insiders at PepGen Inc. have bought $0 and sold $1.04M worth of PepGen Inc. stock.
On average, over the past 5 years, insiders at PepGen Inc. have bought $21.66M and sold $553,564 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,557,593 shares for transaction amount of $27.21M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑02‑09.
List of Insider Buy and Sell Transactions, PepGen Inc.
| 2025-02-26 | Sale | Donnelly Noel | Chief Financial Officer | 1,527 0.005% | $1.68 | $2,565 | +20.08% | |
| 2025-02-26 | Sale | DeLena Mary Beth | General Counsel | 1,432 0.0047% | $1.68 | $2,406 | +20.08% | |
| 2024-07-25 | Sale | Mellion Michelle L | Chief Medical Officer | 7,571 0.0234% | $18.06 | $136,741 | -72.89% | |
| 2024-07-24 | Sale | Mellion Michelle L | Chief Medical Officer | 201 0.0006% | $18.01 | $3,619 | -71.58% | |
| 2024-07-18 | Sale | Mellion Michelle L | Chief Medical Officer | 12,625 0.0427% | $18.20 | $229,804 | -69.61% | |
| 2024-07-16 | Sale | Mellion Michelle L | Chief Medical Officer | 5,901 0.0194% | $18.00 | $106,247 | -71.67% | |
| 2024-07-12 | Sale | Mellion Michelle L | Chief Medical Officer | 3,288 0.0108% | $18.04 | $59,331 | -69.36% | |
| 2024-07-02 | Sale | Mellion Michelle L | Chief Medical Officer | 37 0.0001% | $18.07 | $669 | -65.96% | |
| 2024-07-01 | Sale | Mellion Michelle L | Chief Medical Officer | 875 0.0029% | $18.01 | $15,760 | -68.56% | |
| 2024-06-24 | Sale | Mellion Michelle L | Chief Medical Officer | 9,260 0.0291% | $18.19 | $168,427 | -67.26% | |
| 2024-06-12 | Sale | Mellion Michelle L | Chief Medical Officer | 1,086 0.0034% | $18.06 | $19,615 | -63.41% | |
| 2024-06-11 | Sale | Mellion Michelle L | Chief Medical Officer | 500 0.0016% | $18.04 | $9,022 | -63.45% | |
| 2024-06-06 | Sale | Mellion Michelle L | SVP, Clinical Development | 1,411 0.0045% | $18.00 | $25,398 | -60.84% | |
| 2024-06-05 | Sale | Mellion Michelle L | SVP, Clinical Development | 7,245 0.0223% | $18.09 | $131,062 | -62.43% | |
| 2024-05-17 | Sale | Svenstrup Niels | SVP, Chem. Mfg & Controls | 10,000 0.0306% | $13.41 | $134,100 | -41.38% | |
| 2024-02-09 | RA CAPITAL MANAGEMENT, L.P. | 2.56M 10.4935% | $10.64 | $27.21M | -33.63% | |||
| 2023-11-30 | McArthur James G | President and CEO | 1,694 0.006% | $4.17 | $7,056 | +115.10% | ||
| 2023-06-08 | Sale | McArthur James G | President and CEO | 2,381 0.0098% | $16.04 | $38,188 | -55.64% | |
| 2023-06-07 | Sale | McArthur James G | President and CEO | 8,419 0.0366% | $16.23 | $136,618 | -53.27% | |
| 2023-06-06 | Sale | McArthur James G | President and CEO | 18,150 0.076% | $16.18 | $293,660 | -54.80% |
Total: 30
*Gray background shows transactions not older than one year
Insider Historical Profitability
16.01%
| RA CAPITAL MANAGEMENT, L.P. | 9179273 28.0777% | $10.05M | 1 | 0 | <0.0001% | |
| Oxford Science Enterprises plc | 10 percent owner | 4755388 14.5459% | $5.21M | 1 | 0 | +7.35% |
| Shah Rajeev M. | 1302600 3.9844% | $1.43M | 1 | 0 | +7.35% | |
| Deerfield Private Design Fund V, L.P. | 476813 1.4585% | $522,110.24 | 1 | 0 | +7.35% | |
| KEATING LAURIE | director | 4166 0.0127% | $4,561.77 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$459,011,221 | 33 | 33.04% | $37.75M | |
$167,476,357 | 20 | -1.54% | $37.23M | |
$52,611,464 | 19 | 2.74% | $38.23M | |
$20,234,041 | 17 | 2.08% | $32.49M | |
$7,733,516 | 17 | 73.42% | $32.75M |
PEPG Institutional Investors: Active Positions
| Increased Positions | 32 | +48.48% | 4M | +17.42% |
| Decreased Positions | 25 | -37.88% | 5M | -18.72% |
| New Positions | 12 | New | 3M | New |
| Sold Out Positions | 13 | Sold Out | 1M | Sold Out |
| Total Postitions | 73 | +10.61% | 25M | -1.3% |
PEPG Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Ra Capital Management, L.P. | $15,821.00 | 32.39% | 10.69M | 0 | 0% | 2024-12-31 |
| Rtw Investments, Lp | $4,726.00 | 9.68% | 3.19M | +3M | New | 2024-12-31 |
| Viking Global Investors Lp | $2,194.00 | 4.49% | 1.48M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $1,903.00 | 3.9% | 1.29M | +197,178 | +18.11% | 2024-12-31 |
| Suvretta Capital Management, Llc | $1,738.00 | 3.56% | 1.17M | -486,611 | -29.3% | 2024-12-31 |
| Vanguard Group Inc | $1,351.00 | 2.77% | 912,670 | -6,745 | -0.73% | 2024-12-31 |
| Perceptive Advisors Llc | $1,228.00 | 2.51% | 829,536 | -580,902 | -41.19% | 2024-12-31 |
| Laurion Capital Management Lp | $1,200.00 | 2.46% | 810,761 | 0 | 0% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $1,184.00 | 2.42% | 800,000 | -327,536 | -29.05% | 2024-12-31 |
| Orbimed Advisors Llc | $966.00 | 1.98% | 653,016 | -144,342 | -18.1% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.